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For decades reproductive tract infections (RTIs) have been hypothesized to play a role in uterine fibroid devel-
opment. The few previous studies conducted used self-reported history of RTIs and had inconsistent findings. We
investigated this hypothesis further using serological analysis, an immunological measure of past exposure. We
focused on herpes simplex virus type 2 (HSV-2) because prior published data have suggested a possible associ-
ation with fibroids, and serology for HSV-2 is much more sensitive than self-report. We used cross-sectional enroll-
ment data from African-American women enrolled in a prospective study of fibroid incidence and growth (recruited
2010–2012) in the Detroit, Michigan, area. Thewomenwere aged 23–34 years and were screened for fibroids using
a standardized ultrasound examination at their enrollment. Age- andmultivariable-adjusted logistic regressionmod-
els were used to estimate odds ratios. Of 1,696 participants, 1,658 had blood samples and HSV-2 serology results;
22% of participants with serology results had fibroids. There was no significant association between HSV-2 sero-
positivity and the presence of fibroids (multivariable-adjusted odds ratio = 0.94, 95% confidence interval: 0.73,
1.20), nor were there any associations with size of the largest fibroid, number of fibroids, or total fibroid volume.
Our data provide no evidence for an influence of HSV-2 exposure on fibroid risk in young African-American
women. Further study of other serologically measured RTIs is warranted.
herpes simplex virus type 2; seroprevalence; uterine fibroids
Abbreviations: DMPA, depot medroxyprogesterone acetate; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type
2; RTI, reproductive tract infection; SELF, Study of Environment, Lifestyle, and Fibroids.
Uterine fibroids are among the most common gynecolog-
ical conditions affecting women in the United States during
their reproductive years (1). Based on ultrasound screening of
randomly selected women, the estimated cumulative inci-
dence of fibroid tumors by age 50 years is more than 80%
for African-American women and close to 70% for white
women (2). Symptoms resulting from fibroids (pain, severe
bleeding, and reproductive problems) are the leading reason
for hysterectomy in the United States, and the total annual
costs of fibroids are as high as $34 billion (3).
Fibroids are hormone-dependent, benign tumors of the uter-
ine smooth muscle. Their etiological causes are largely un-
known, but established risk factors include African-American
heritage (African Americans are 2–3 times as likely as white
women to have clinically recognized fibroids (2)), older age
(up to the age of menopause), younger age at menarche, and
nulliparity (4–6). Three studies have found that progestin-
only injectables (such as depot medroxyprogesterone acetate
(DMPA)) are protective (5, 7, 8). Heavier alcohol use may be
a risk factor, although the number of studies is small (9, 10).
A hypothesis was raised decades ago that reproductive
tract infections (RTIs) may play a role in fibroid development
(11). Both RTIs and fibroids disproportionately burden
African-American women, and certain RTIs can lead to con-
ditions such as chronic pelvic infection that could result in
inflammatory reactions (11). This hypothesis is consistent
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with another theorized mechanism of fibroid pathogenesis
in which infection can stimulate an inflammatory immune
response that can facilitate the initiation of tissue damage, re-
sulting in tissue repair or regeneration (increased extracellular
matrix, cell proliferation, decreased apoptosis), leading to the
formation and growth of uterine fibroids (12, 13). Further-
more, fibroids were found to be associated with serologically
determined Chagas disease (caused by a protozoan parasite)
(14), and Epstein-Barr virus was found to infect smooth mus-
cle cell tumors at sites outside of the uterus (15).
However, the limited data on associations between RTIs
and fibroid risk have yielded inconsistent findings (4, 16,
17). One of the primary aims for undertaking the Study of En-
vironment, Lifestyle, and Fibroids (SELF), a large study of
fibroids in African-American women, was to fill this data
gap (18). The data from prior studies suggested positive asso-
ciations between fibroids and pelvic inflammatory disease
(16), chlamydia (16), genital herpes (4), trichomonas (4),
bacterial vaginosis (4, 17), and syphilis (4). We recently pub-
lished self-reported RTI data from SELF that showed no
strong associations with fibroids (17). We did find that
women reporting a history of bacterial vaginosis had some-
what elevated odds of multiple fibroids (≥2) and larger
total fibroid volume (≥2 cm3), and women reporting a history
of chlamydia tended to have fewer and smaller fibroids (17).
However, all of these previous reports measured RTI history
with questionnaire data, which can be plagued by recall error
as well as misclassification due to the asymptomatic nature
of most RTIs (19–22). An immunological measure of expo-
sure, namely serological analysis (diagnostic identification of
antibodies in the serum that remain after infection), would
provide a more accurate assessment of exposure than self-
reported RTI history.
Herpes simplex virus type 2 (HSV-2), the main cause of
genital and neonatal herpes, is a common RTI in the United
States (23). Comparedwithwomen of other racial/ethnic groups
in theUnited States, African-Americanwomen have the highest
seroprevalence of HSV-2 (50% for 14- to 49-year-olds between
2007 and 2010) (24). Other main risk factors for HSV-2 include
higher numbers of sexual partners, heavy alcohol use, low so-
cioeconomic status, being unpartnered rather than married or
cohabiting, and lack of consistent condom use (24–28). Also,
DMPA use may increase risk of HSV-2 seroconversion (29,
30), and age at menarche has been found to be associated
with HSV-2 (31) and has been identified as a predictor of sex-
ual behavior that is highly associated with HSV-2 (32, 33).
HSV-2 antibodies have been shown to persist for years
after infection (34), and serological testing for HSV-2 can be
done sensitively and specifically for past exposure to HSV-2
(35). Cell culture and polymerase chain reaction are the recom-
mended laboratory tests for people who have active lesions
or ulcers present (36). However, most HSV-2 infections are
asymptomatic or unrecognized (in a study by Fanfair et al.
(24), more than 85% of seropositive African-American women
reported no history of diagnosis). Thus, seropositivity toHSV-2
is the best estimate of past, cumulative exposure (24, 25).
Building upon previous work, in which a positive associ-
ation between self-reported HSV-2 and fibroids was found
(4), our primary aim was to investigate the relationship be-
tween HSV-2 and fibroids in a large cohort with ultrasound
screening for fibroids and serological measurement of expo-
sure. This study was, to our knowledge, the first to investigate
the association of fibroids with HSV-2 exposure assessed se-
rologically. We hypothesized that women seropositive for
HSV-2 would have a higher prevalence of fibroids than
women seronegative for HSV-2. We also explored the rela-
tionship between HSV-2 seropositivity and number, size,
and total volume of fibroids.
METHODS
Study participants and data collection
We used transvaginal ultrasound results, self-reported
questionnaire data, and stored frozen serum specimens from
participants in SELF, an ongoing study based in the Detroit,
Michigan, area. SELF is a prospective cohort study of fibroid
development. Enrollment data and specimen collection pro-
tocols have been described previously (18). In brief, from
November 2010 to December 2012, the study recruited
1,696 African-American volunteers; all of the women were
aged 23–34 years. Women were not eligible for SELF if they
had previously been diagnosed with uterine fibroids; had had
a hysterectomy; had ever taken medication to treat lupus,
Grave’s disease, Sjögren syndrome, scleroderma, or multiple
sclerosis; or had ever had any type of cancer treated with radi-
ation or chemotherapy. The study was approved by the institu-
tional review boards of the National Institute of Environmental
Health Sciences (Research Triangle Park, North Carolina) and
the Henry Ford Health System (Detroit, Michigan).
Fibroid assessment
Transvaginal ultrasound, the standard procedure for the de-
tection and diagnosis of fibroids, was used in this study (37).
Fibroids were assessed by study sonographers as described
previously (18) at one of 3 clinics. Focal fibroids of 0.5 cm
diameter or greater were measured in triplicate. For each
measurement, the 3 perpendicular diameters (longitudinal,
anterior-posterior, and transverse) were recorded.
Outcome definitions
The primary outcome of this study was the presence of fi-
broids (yes or no) at the transvaginal ultrasound examination
completed at enrollment. Fibroids were classified as “ques-
tionable” when at least 1 diameter could not be measured.
Participants with at least 1 fibroid or questionable fibroid
greater than or equal to 0.5 cm in diameter at the enrollment
ultrasound were considered to have fibroids, and all women
without a fibroid or questionable fibroid at least 0.5 cm in di-
ameter were considered not to have fibroids. The secondary
outcomes for this analysis were size of the largest fibroid,
number of fibroids, and total fibroid volume. The size of
the largest fibroid was estimated by averaging the maximum
diameter (longitudinal, anterior-posterior, or transverse) of
each of the triplicate fibroid measurements. Fibroid volume
(cm3) was measured by computing the volumes of each of
the triplicate fibroid measurements using the ellipsoid formula
(longitudinal × anterior-posterior × transverse × 0.5233) and
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averaging across the 3 volumes. Total fibroid volume (cm3)
was calculated by adding the average volumes from each of
a woman’s fibroids. Total fibroid volume was not computed
for women with only questionable fibroids (n = 6) in whom at
least 1 diameter was not measured.
HSV-2 assessment
HSV-2 antibody serostatus was assessed in the Interna-
tional Sexually Transmitted Diseases Research Laboratory
at Johns Hopkins University (Baltimore, Maryland) using
the Focus Diagnostics HerpeSelect 2 ELISA IgG test (Focus
Diagnostics, Cypress, California) according to the package
instructions (38). This type-specific assay (glycoprotein gG2)
allows for the qualitative detection of HSV-2 immunoglobu-
lin G antibodies with or without the presence of herpes sim-
plex virus type 1 (HSV-1) (38). Antibody levels greater than
1.10 optical density units were categorized as seropositive
and levels less than 0.90 were seronegative. Levels of 0.9
to 1.10 were considered indeterminate, and those samples
were retested. The level of antibody response cannot be used
to determine active infection or recency of initial infection.
For quality control, we included blinded duplicate sam-
ples. Aliquots were created from unused serum samples col-
lected from SELF participants during a special blood drawing
performed 6 months after enrollment (18). Two aliquots from
each of 42 specimens served as 84 blinded control samples.
Forty of the 42 duplicate pairs had identical results. For each
of the other 2 discordant pairs, 1 of the aliquots was consid-
ered indeterminate. The result for the other aliquot of each of
these 2 discordant pairs matched the result found for the en-
rollment specimen from the same participant.
Statistical analyses
Due to the use of telephone and Web-based interview
methods that did not allow participants to skip questions,
there was a minimal amount of missing data on covariates.
However, participants were able to respond “prefer not to
answer.” This response (<1%) was coded as missing, and
complete case analysis was performed. Variables were cate-
gorized on the basis of the distribution of the data and com-
parability with the literature. All analyses were completed
using data from women who had blood samples taken at en-
rollment. Standard descriptive statistics were performed for
all variables of interest. We also evaluated the relationship
between HSV-2 serostatus and number of sexual partners
and age at first intercourse for comparison with the literature.
All analyses were conducted using SAS, version 9.3 (SAS
Institute, Inc., Cary, North Carolina).
Primary analyses. Logistic regression was used to com-
pute odds ratios and 95% confidence intervals to evaluate
the relationship between HSV-2 serostatus and the presence
of fibroids. Although the relative odds overestimate the relative
risk for associations with an outcome as common as fibroids,
overestimation is minimal for weak associations and does not
affect statistical tests. Potential confounders and variables of
interest were determined based on a review of the literature,
and a directed acyclic graph (39) was used to provide a concep-
tual framework. Potential confounders included age in years
(continuous), age at menarche (7–10 years or 11–19 years), al-
cohol consumption (low, moderate, or heavy), and use of
DMPA (ever or never). The alcohol-consumption variable re-
flected the drinking level each woman reported for the age(s)
at which she was drinking the most. Low alcohol consumption
was defined as having had less than 10 alcoholic drinks in a
year. Heavy drinkers were those who usually consumed 6 or
more drinks on days when they imbibed alcohol or who con-
sumed 4 or more drinks per sitting at least 2–3 times a month.
All others were considered moderate drinkers. Variables
of interest based on the literature included education (high
school graduation, General Educational Development certif-
icate, or less; some college, an associate degree, or technical
education; or bachelor’s, master’s, or doctoral degree), and
body mass index (15–24, 25–29, 30–34, or ≥35), which
was calculated as weight (kg)/height (m)2. Parity (nullipa-
rous or parous) was included to increase precision because
of the consistent association between parity and fibroids in
the literature. We included age, age at menarche, parity,
and DMPA use in a full model a priori. The alcohol variable
was not included a priori because the amount of literature
supporting an association between alcohol consumption
and fibroids is small. After adding alcohol and the additional
variables of interest, we used backwards elimination and the
10%-change-in-estimate approach to determine the mini-
mally adjusted final model. Only the covariates included a
priori remained in the final model.
Secondary analyses. In a secondary analysis, we exam-
ined the association between HSV-2 and fibroid characteris-
tics: size of the largest fibroid, number of fibroids, and total
fibroid volume. Median values rounded to the nearest whole
number were used to determine category cutpoints for size
of the largest fibroid and total fibroid volume (2 cm and
2 cm3, respectively). We used multinomial logistic regression
models to estimate the odds ratios and 95% confidence inter-
vals for the associations of HSV-2 serostatus with fibroid size,
number, and total volume. Moreover, because the majority of
HSV-2 infections are asymptomatic, self-reported infections
are likely to be those that are symptomatic. Thus, in a second-
ary analysis, we evaluated the multivariable-adjusted odds ra-
tios and 95% confidence intervals for the relationship between
HSV-2 and fibroid presence using a 3-level exposure variable:
0 = seronegative, 1 = not symptomatic (seropositive with no
self-reported diagnosis), and 2 = symptomatic (seropositive
with self-reported diagnosis). For both of these secondary
analyses, we adjusted for the same confounders as those in-
cluded in the final model in the primary analysis (age, age at
menarche, parity, and DMPA use).
Sensitivity analyses. To evaluate the robustness of our
findings, we examined multivariable-adjusted odds ratios and
95% confidence intervals for the association of HSV-2 with
fibroids in a series of sensitivity analyses by restricting or strat-
ifying the sample. Cervical treatment is an indicator of cervical
lesions secondary to persistent human papillomavirus infec-
tion and was found to be inversely associated with fibroids
in a previous study (40). Thus, any HSV-2 associations we ob-
served might have been attenuated. Therefore, we repeated the
primary analyses after excluding those who reported cervical
treatment (231 women excluded). To evaluate age as an effect
modifier (due to possible decline in antibody levels over time),
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Table 1. Selected Enrollment Characteristics of African-American Women Aged 23–34 Years According to Herpes
Simplex Virus Type 2Serostatus (n = 1,658), Studyof Environment, Lifestyle, and Fibroids, Detroit, Michigan, 2010–2012
Covariate
HSV-2
Seropositive
(n = 789)
HSV-2
Seronegative
(n = 869)
No. % No. %
Age, years
23–26 191 24 319 37
27–30 284 36 286 33
31–35a 314 40 264 30
Education
High-school graduate, GED certificate, or less 235 30 129 15
Some college, associate degree, or technical education 409 52 423 49
Bachelor’s, master’s, or doctoral degree 144 18 317 36
Missing 1 0
Body mass indexb
15–24 164 21 164 19
25–29 157 20 186 21
30–34 141 18 177 20
≥35 327 41 342 39
Alcohol consumptionc
Low 198 25 240 28
Moderate 231 29 309 36
Heavy 360 46 320 37
Parity
Nulliparous 238 30 412 47
Parous 551 70 457 53
DMPA
Never used 383 49 566 65
Ever used 406 51 303 35
Age at menarche, years
7–10d 157 20 142 16
11–19 632 80 727 84
No. of sexual partners before age 20 years
≤1e 154 19 268 31
2–5 399 51 413 48
≥6 234 30 187 21
Missing 2 1
Age at first sexual intercourse, years
≤14 284 36 196 23
15–16 274 35 287 33
≥17e 231 29 383 44
Missing 0 3
Abbreviations: DMPA, depot medroxyprogesterone acetate; GED, General Educational Development; HSV-2,
herpes simplex virus type 2.
a No persons over 34 years of age were recruited, but some 34-year-olds had turned 35 by the time they had their
ultrasound examination.
b Body mass index was calculated as weight (kg)/height (m)2.
c The alcohol-consumption variable reflected the drinking level each woman reported for the age(s) at which she
was drinking the most. Low alcohol consumption was defined as having had less than 10 alcoholic drinks in a year.
Heavy drinkers were those who usually consumed 6 or more drinks on days when they imbibed alcohol or who
consumed 4 or more drinks per sitting at least 2–3 times a month. All others were considered moderate drinkers.
d Categorized to identify early age at menarche, the category associated with fibroids.
e Includes participants who reported never having had sex.
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we evaluated the association between HSV-2 and fibroid pres-
ence in 2 age strata (23–29 years or 30–35 years).
To investigate temporality of HSV-2 exposure in relation to
fibroid development, we assessed the association between
HSV-2 and fibroids among strata of size of the largest fibroid
(<2 cm vs.≥2 cm). Thosewith smaller fibroids aremore likely
to have developedfibroidsmore recently and thusmay bemore
likely to have had exposure to HSV-2 before fibroid develop-
ment compared with women with larger fibroids. In addition,
we looked at the association of HSV-2 and fibroid presence
within 2 strata of number of sexual partners before age 20
years (0 or 1 vs. 2 or more). Those with more sexual partners
before the age of 20 years would have been more likely to be
exposed to HSV-2 prior to fibroid development.
A total of 1,696 women were enrolled in the SELF study.
HSV-2 serology was conducted for the 98% of participants
with available enrollment blood samples (n = 1,662). Four
of the samples had indeterminate results that were excluded.
Therefore, our analyses were performed on the 1,658 partic-
ipants with HSV-2 serology results.
RESULTS
The median age of our cohort at enrollment was 29 years,
and the median age at menarche was 12 years. The majority
of participants were parous, and more than 40% had used
DMPA. Forty-seven percent (n = 869) of the participants were
seropositive for HSV-2. HSV-2 seropositive women tended to
be older, to be less educated, to be heavier drinkers, to be parous,
to be more likely to have ever used DMPA, to have had more
sexual partners before age 20 years, and to have been younger
at first sex compared with those who were seronegative for
HSV-2 (Table 1).
Twenty-two percent of women had fibroids discovered at
ultrasound screening (Table 2). Of those with fibroids, the
size of the largest fibroid was less than 2 cm for 61%; 63%
had only 1 fibroid. Among 51% of participants with fibroids,
the total fibroid volume was less than 2 cm3.
In primary analyses, the odds of fibroids were similar for
those who were HSV-2-seropositive and those who were
HSV-2-seronegative, in both age- and multivariable-adjusted
models (multivariable-adjusted odds ratio = 0.94, 95% confi-
dence interval: 0.73, 1.20) (Table 2). In secondary analyses,
we evaluated size of the largest fibroid, number of fibroids,
and total fibroid volume as the outcomes (Figure 1). There
was no significant association between HSV-2 exposure
and fibroid size, number, or total volume.
We also examined the relationship between symptomatic
herpes and fibroid presence based on a combination of self-
reported genital herpes and serology data (Table 3). Only
16% ofwomenwhowere seropositive for HSV-2 reported hav-
ing had a genital herpes diagnosis (sensitivity for self-reported
Table 2. Herpes Simplex Virus Type 2 Serostatus in Relation to Fibroids Among African-American Women Aged
23–34 Years (n = 1,658), Study of Environment, Lifestyle, and Fibroids, Detroit, Michigan, 2010–2012
HSV-2
Serostatus
No. of
Women
Fibroids
Detected Age-
Adjusted OR 95% CI
Multivariable-
Adjusteda OR 95% CI
No. %
Seronegative 869 195 22 1.00 Referent 1.00 Referent
Seropositive 789 170 22 0.82 0.64, 1.04 0.94 0.73, 1.20
Abbreviations: CI, confidence interval; HSV-2, herpes simplex virus type 2; OR, odds ratio.
a Adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity.
Adjusted Odds Ratio
0.6 1.0 1.6
aOR (95% CI)
1.00 (Referent)
0.88 (0.65, 1.19)
1.04 (0.72, 1.51)
0.95 (0.71, 1.27)
0.92 (0.63, 1.34)
0.97 (0.70, 1.34)
0.94 (0.67, 1.33)
Variable
No HSV-2
Size of Largest Fibroid, cm
<2
≥2
No. of Fibroids
1
≥2 
Total Volume, cm3
<2
≥2 
Figure 1. Size of largest fibroid, number of fibroids, and total fibroid volume in relation to herpes simplex virus type 2 (HSV-2) serostatus among
young African-American women with fibroids (n = 365), Study of Environment, Lifestyle, and Fibroids, Detroit, Michigan, 2010–2012. The partici-
pants were aged 23–34 years. Odds ratios (aORs) and 95% confidence intervals (CIs) were adjusted for age, age at menarche, depot medroxy-
progesterone acetate use, and parity.
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HSV-2 exposure). However, 98% of those who were sero-
negative reported no diagnosis of genital herpes (specific-
ity). Those who were seropositive and reported an HSV-2
diagnosis (our measure of symptomatic herpes) did not have
higher odds of fibroids. Furthermore, the lack of an associa-
tion between HSV-2 and fibroids remained consistent across
the sensitivity analyses performed (Table 4).
DISCUSSION
Our study did not show an association between HSV-2 and
the presence of fibroids or the size, number, or total volume
of fibroids. Even among women who were seropositive and
had genital herpes severe enough to warrant reporting a clin-
ical diagnosis, there was no association with fibroids. In
addition, the lack of an association was consistent across var-
ious sensitivity analyses: excluding women with cervical
treatment and stratifying by size of the largest fibroid, age,
and number of sexual partners before age 20 years.
Our findings are consistent with a previous study on this
same population that evaluated several self-reported RTIs,
showing no association of genital herpes with fibroids (17).
Two other studies have investigated the association between
self-reported genital herpes and the presence of fibroids
(4, 16). A clinic-based case-control study of premenopausal
women (aged 18–55 years) showed no association of genital
herpes with clinically detected fibroids (16). The Uterine
Fibroid Study (4), a cross-sectional study that used ultra-
sound to screen randomly selected members of an urban
health plan aged 35–49 years for fibroids, found suggestions
of a positive association of self-reported genital herpes with
fibroids in both African-American and white women (4).
However, these findings were not precise enough to rule
out associations due to chance. A small pilot study investi-
gated whether pathogens were present in fibroid tissue; spec-
imens from 20 Uterine Fibroid Study participants who had
reported a history of sexually transmitted disease or multiple
sexual partners were tested for viral DNA matching HSV-1,
HSV-2, cytomegalovirus, human herpes virus (types 6, 7,
and 8), and Epstein-Barr virus using polymerase chain reac-
tion (4). None of these pathogens was detected in the tumor
samples.
Our study had several limitations. It was a cross-sectional
analysis. Thus, the timing of acquisition of HSV-2 infection
in relation to fibroid development is unknown. However, it is
likely that exposure occurred before disease onset for most
women. More than half the women who self-reported genital
herpes reported that their first diagnosis was before the age of
22 years, and approximately 45% of newHSV-2 infections in
the United States are among persons aged 15–24 years (23).
Also, most of the fibroids were small, suggesting relatively
recent development, and fibroid development in African
Americans appears to be infrequent before the mid-20s (18,
41). Finally, the median amount of time between the first self-
reported HSV-2 diagnosis and study enrollment was 6 years,
and because antibody titers persist for years after infection
(34), even exposure to HSV-2 multiple years prior to enroll-
ment should have been captured.
We did not use theWestern blot test, the gold standard me-
thod for HSV-2 serology (35, 42). However, the HerpeSelect
2 assay we used (38) has been found to perform very well for
HSV-2 infections, with sensitivity between 96% and 100%
and specificity between 97% and 98% (43, 44) in comparison
Table 3. Symptomatic and Asymptomatic Serologically Detected
Herpes Simplex Virus Type 2 in Relation to Fibroids Among
African-American Women Aged 23–34 Years (n = 1,641), Study of
Environment, Lifestyle, and Fibroids, Detroit, Michigan, 2010–2012
HSV-2 Statusa No. ofWomen
Fibroids
Detected ORb 95% CI
No. %
Seronegative 853 189 22 1.00 Referent
Symptomaticc
No 664 146 22 0.99 0.76, 1.29
Yes 124 24 19 0.77 0.47, 1.26
Abbreviations: CI, confidence interval; HSV-2, herpes simplex virus
type 2; OR, odds ratio.
a Limited to participants with data on HSV-2 symptomatology; 17
participants had missing data (1 with missing data on self-reported
genital herpes and 16 who reported genital herpes but were HSV-2-
seronegative).
b Adjusted for age, age at menarche, depot medroxyprogesterone
acetate use, and parity.
c Defined as HSV-2-seropositive participants who reported having
been diagnosed with genital herpes (“Yes”) or not having been
diagnosed with genital herpes (“No”).
Table 4. Sensitivity Analyses of the Association of Fibroids With
Herpes Simplex Virus Type 2 Serostatus Among African-American
Women Aged 23–34 Years, Study of Environment, Lifestyle, and
Fibroids, Detroit, Michigan, 2010–2012
No. of
Women OR
a 95% CI
Full sample 1,658 0.94 0.73, 1.20
Exclusion of women with prior
cervical treatment
1,426 0.95 0.72, 1.24
Stratified by age, years
23–29 934 0.84 0.58, 1.22
≥30 724 1.01 0.72, 1.41
Stratified by size of largest
fibroid, cmb
<2 224 0.88 0.65, 1.18
≥2 141 1.06 0.73, 1.54
Stratified by no. of sexual
partners before age
20 yearsc
0–1 422 0.99 0.60, 1.64
≥2 1,233 0.91 0.68, 1.21
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for age, age at menarche, depot medroxyprogesterone
acetate use, and parity.
b Referent was the group of 1,293 participants without fibroids.
c Three participants had missing data for number of sex partners
before age 20 years.
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with the Western blot. The Western blot technique is not
approved by the US Food and Drug Administration and is
more complex, more costly, less time-efficient, and much
less widely available than the enzyme-linked immunosorbent
assay (45). In addition, we did not capture persons who had a
very recent infection, because it can take weeks to months
after infection for immunoglobulin G antibodies to be de-
tected. However, because we seek to measure past exposure,
ideally at the time of fibroid development, low sensitivity for
very recent infections did not jeopardize our assessment of
cumulative exposure to HSV-2.
In addition, HSV-2 seroprevalence alone underestimates
the prevalence of genital herpes simplex virus infection due
to the omission of genital infections caused solely by HSV-1,
which are increasing in incidence (46). However, because
HSV-1 also causes orolabial infections, which are very prev-
alent (46), a large proportion of the population will have an-
tibodies to HSV-1, and we would not be able to distinguish
orolabial HSV-1 infection from genital HSV-1 infection.
Thus, the value of the added information to be gained from
measuring HSV-1 is unclear.
Finally, our sample was a volunteer sample of women.
However, the seroprevalence of HSV-2 in our cohort (47%)
was very similar to the seroprevalence of 50% for African-
American women in the United States (24). Furthermore,
22% of the women in our cohort had fibroids at ultrasound
screening, which falls within the range of prior US studies
that conducted ultrasound screening (2, 4, 41, 47).
Our study also had several strengths. This was, to our
knowledge, the first study to investigate the relationship be-
tween HSV-2 and fibroids using an immunological measure
of exposure. Our blinded quality-control samples demon-
strated low measurement error in HSV-2 serostatus. Previous
studies have used only self-reported diagnosis of genital her-
pes as the exposure measurement, which is problematic due
to the high prevalence of asymptomatic infection. Further-
more, we used a standard and valid measure of fibroid status
based on systematic ultrasound screening rather than fibroids
clinically detected because of symptoms or incidental detec-
tion. The number, diameter, and volume of the fibroids were
systematically measured, which enabled us to examine asso-
ciations with these separate characteristics. Our sample size
was sufficient to provide good precision for the main hypoth-
eses. In addition, most women with a history of HSV-2 are
unaware of their exposure status, making it very unlikely
that women without fibroids who had a history of HSV-2
exposure would be more likely to enroll in the study than
those without HSV-2; thus, there was limited potential for se-
lection bias. Our study also had extensive data with which to
assess potential confounding and minimal missing data. In
addition, we conducted sensitivity analyses to evaluate poten-
tial bias.
Overall, based on our findings in a large cohort of young
(ages 23–34 years) African-American women, HSV-2 sero-
positivity does not appear to be a risk factor for fibroids in this
group. However, this does not suggest that other RTIs do not
play a role in fibroid development. Further study of other se-
rologically measured RTIs is still warranted, as are prospec-
tive studies of the relationship between RTIs and fibroid
growth.
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